Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasms 7Carcinoma 5Neoplasm Metastasis 3Prostatic Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Vipoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Meningeal Carcinomatosis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Hormone Refractory Prostate Cancer 1Gastrinoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms, Male 1

Interventions

Octreotide 4vatalanib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Temozolomide 1Sorafenib 1Salts 1Melphalan 1Leucovorin 1Irinotecan 1Immunoglobulin G 1Gefitinib 1Fluorouracil 1Everolimus 1Disulfides 1Capecitabine 1Biological Therapy 1Bevacizumab 1Acetates 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vipoma × epothilone B × Clear all
NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Novartis

Phase 2 Completed
33 enrolled
EndocrineNET

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡